Buprenorphine Transdermal Patch and Meprobamate: Interaction Details
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- AI-assisted, written
- AI is used only to summarize verified clinical information, never the open internet.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
A close look at the Buprenorphine Transdermal Patch and Meprobamate interaction:
Meprobamate
- Amosene
- Bamate
- Equanil
- Mepriam
- Meprospan
- Miltown
- Neuramate
- Tranmep
Buprenorphine Transdermal Patch
- Butrans
- Belbuca
- Sublocade
- Buprenex
- Brixadi
What Happens When You Take Buprenorphine Transdermal Patch With Meprobamate
What can happen when they are taken together (rated Major)
An increased risk of and
Interaction Deep Dive
A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →
Giving buprenorphine together with a depressant can produce CNS depression, which raises the risk of respiratory depression, profound , coma, and death. Stopping the CNS depressant is favored over continuing both drugs.
Depending on the situation, it may be appropriate to monitor the patient in a higher level of care or to taper. In other cases, the better course may be to gradually taper the patient off a prescribed CNS depressant or to reduce it to the lowest effective dose.
When cannot be avoided, monitor carefully and manage with caution, and consider other options for treating anxiety or insomnia.2 A Swedish epidemiological study found that patients on methadone- or buprenorphine-based medication-assisted treatment (MAT) who also received or other CNS depressants (for example, drugs used for insomnia) had a higher risk of death.
In an analysis of aggregate nationwide death certificate data from 2010 to 2014, most overdose deaths involving buprenorphine or methadone also involved concurrent use of a CNS depressant. Whether the risk of overdose death with CNS depressants differed between buprenorphine and methadone is not known.3
The Buprenorphine Transdermal Patch and Meprobamate Interaction, Explained
Taking these two together can make you dangerously sleepy and slow your breathing. Meprobamate is a calming medicine for anxiety, and the buprenorphine patch is an used for pain (or sometimes opioid use disorder treatment). Both slow down the brain and body, so their effects add up. This can cause heavy drowsiness, trouble breathing, passing out, or in serious cases death.
Please don't stop or change either medicine on your own. Talk with your pharmacist or doctor, who can review whether you need both, adjust doses, or watch you more closely. Avoid alcohol and other sedating medicines unless your care team approves.
and () between meprobamate (carbamate sedative-anxiolytic) and transdermal buprenorphine (partial mu-opioid ). Risks include profound , respiratory depression, coma, and death. Severity: major. Evidence: probable. Onset: unspecified.
- Cessation of the CNS depressant is preferred; otherwise taper gradually or use the lowest effective dose. Consider a higher level of care in some cases.
- If is necessary, monitor for sedation and respiratory depression and consider alternatives for anxiety or insomnia.
- Observational data (Swedish MAT cohort, US 2010 to 2014 death certificates) link CNS depressants with overdose death.
- Do not withhold MAT because of CNS depressant use; untreated OUD carries greater morbidity and mortality.
See the 3 references behind this explanation ↓
From the HelloPharmacist Pharmacy Team
AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .
How we build these pages · How we use AI · Our editorial policy
Why Buprenorphine Transdermal Patch and Meprobamate Interact
The likely mechanism
How to Manage the Buprenorphine Transdermal Patch and Meprobamate Interaction
Your care team may review whether you still need both medicines. Options they may consider include gradually tapering meprobamate, using the lowest effective dose, or choosing a different treatment for anxiety or sleep. If you need both, they may monitor you more closely for slowed breathing and sleepiness, and doses may need to be adjusted and individualized.
- Keep taking both exactly as prescribed unless your prescriber tells you otherwise.
- Tell your pharmacist and prescriber about all sedating medicines and alcohol use.
- If you are receiving buprenorphine for use disorder, do not stop it on your own; your team can manage the risk.
- Ask family to seek emergency help for extreme drowsiness, slow or shallow breathing, or trouble waking.
Management is individual — confirm any change with your pharmacist or prescriber.
Questions for Your Pharmacist
- Does my dose of Buprenorphine Transdermal Patch or Meprobamate need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there another option that avoids this interaction?
Literature Reports
2 reports from the published literature. Each one is headed by the title of the published study it comes from.
What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.
-
Report 1 · Study title
Drug Safety Communications: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks
A Swedish epidemiological study reported that patients receiving methadone- or buprenorphine-based medication-assisted treatment (MAT) together with or other depressants (e.g., drugs used to treat insomnia) face an increased risk of death. For the period from July 1, 2005 to December 31, 2012, the investigators analyzed the risk of fatal overdose, non-overdose related mortality, and all-cause mortality in MAT patients (aged 18 to 50), comparing periods of prescribed CNS depressant use with periods without CNS depressant therapy.
Combined MAT and benzodiazepine treatment was associated with an elevated risk of all-cause mortality (adjusted hazard ratio (HR) 1.44; 95% CI, 0.93 to 2.23) and non-overdose related mortality (HR 1.74; 95% CI 1.00 to 3.01), but these findings were not considered statistically significant. of MAT with non-benzodiazepines was also associated with elevated risks of fatal overdose, non-overdose mortality, and all-cause mortality, yet only the findings for fatal overdose and all-cause mortality were considered statistically significant, at HR 2.34 (95% CI, 1.37 to 3.99) and HR 1.33 (95% CI, 1.12 to 2.45), respectively. The benzodiazepine and non-benzodiazepine cohorts were not compared with each other, because the authors did not adjust for the indication for which the drugs were used.3
-
Report 2 · Study title
Drug Safety Communications: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks
A study of aggregate nationwide death certificate data from 2010 to 2014 identified 3495 drug overdose deaths reported in 2014. Methadone and other depressants were often named as contributors to these deaths.
Concurrent ALPRAZolam use was reported in 18.1% of cases, followed by oxyCODONE (10.1%), cocaine (9.6%), heroin (9%), and diazePAM (6.6%). The FDA reported 322 drug overdose deaths involving buprenorphine in 2014.
Among these 322 deaths, 32.9% involved ALPRAZolam, 17.4% involved clonazePAM, 11.2% involved diazePAM, 11.2% involved heroin, and 9.9% involved fentaNYL. The absolute number of deaths involving methadone was 10 times that involving buprenorphine, although confounding factors and differences in drug utilization were not taken into account. Whether the risk of overdose death with CNS depressant drugs differed between buprenorphine and methadone is unknown.3
Buprenorphine Transdermal Patch and Meprobamate: Common Questions
How serious is the Buprenorphine Transdermal Patch and Meprobamate interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How is the Buprenorphine Transdermal Patch and Meprobamate interaction managed?
Your care team may review whether you still need both medicines. Options they may consider include gradually tapering meprobamate, using the lowest effective dose, or choosing a different treatment for anxiety or sleep. If you need both, they may monitor you more closely for slowed breathing and sleepiness, and doses may need to be adjusted and individualized. Keep taking both exactly as prescribe… Management is individual — always follow your own care team's guidance.
Is there an alternative to taking Buprenorphine Transdermal Patch with Meprobamate?
The interaction record says a different medicine may be considered in place of one of these two.
Only your prescriber can decide whether a change fits you, so talk with them before changing either medicine.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Ask About the Buprenorphine Transdermal Patch and Meprobamate Interaction
Ask in your own words about taking Buprenorphine Transdermal Patch and Meprobamate together. The answer comes from this page’s interaction record and both drugs’ own information.
This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.
AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.
References (3)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: SUBUTEX(R) sublingual tablets, buprenorphine sublingual tablets. Indivior Inc (per FDA), North Chesterfield, VA, 2021. DailyMed
- US Food and Drug Administration (FDA): Drug Safety Communications: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. US Food and Drug Administration (FDA). Silver Spring, MD. 2017.
Other Serious Interactions of Buprenorphine Transdermal Patch and Meprobamate
Also serious with Meprobamate
- IsocarboxazidContraindicated
- Acetaminophen and CodeineMajor
- BuprenorphineMajor
- Butorphanol InjectionMajor
Also serious with Buprenorphine Transdermal Patch
These Medications Also Interact With Supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
With Meprobamate
- Activated CharcoalMajor
- KavaMajor
- WineMajor
- 1,4-butanediolMajor
- BeerMajor
- Gamma-hydroxybutyrate (GHB)Major
- L-TryptophanMajor
- AshwagandhaModerate
- + 97 more
Check everything you take with our drug–supplement interaction checker.
Still Have Questions About This Combination?
Every question gets a real answer from a licensed pharmacist — free, as soon as they can.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together.
- Major Potentially serious — often needs a change or close monitoring. This interaction.
- Moderate Can be significant — usually manageable with monitoring.
- Minor Usually limited clinical impact.
Evidence Grades
- EstablishedWell documented — supported by controlled studies or strong clinical data.
- ProbableGood supporting evidence, though not definitively proven. This interaction.
- SuspectedSome evidence suggests this interaction, but it is not well established.
- PossibleLimited or conflicting evidence; the interaction may occur.
- TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.
How Soon It Shows
- RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
- DelayedEffects tend to build up gradually over days to weeks.
- UnspecifiedThe timing of this interaction is not well characterized. This interaction.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.